EGFR and non-small cell lung carcinoma: Here, the effectiveness and safety of allogenic CD8 + CD56+ Natural Killer T (NKT) cell immunotherapy in combination with gefitinib for patients with advanced NSCLC with EGFR mutations was explored (30).